Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HCK5
UPID:
AGO4_HUMAN
Alternative names:
Argonaute RISC catalytic component 4; Eukaryotic translation initiation factor 2C 4
Alternative UPACC:
Q9HCK5; A7MD27
Background:
Protein argonaute-4, also known as Argonaute RISC catalytic component 4 and Eukaryotic translation initiation factor 2C 4, plays a pivotal role in RNA-mediated gene silencing (RNAi). It binds to short RNAs like microRNAs (miRNAs) and represses the translation of mRNAs that are complementary to them. Notably, it lacks endonuclease activity, indicating it does not cleave target mRNAs directly. Additionally, it is essential for RNA-directed transcription and replication of the human hepatitis delta virus (HDV).
Therapeutic significance:
Understanding the role of Protein argonaute-4 could open doors to potential therapeutic strategies.